These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 23274580)

  • 1. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages.
    Cho J; Jeong J; Sung J; Sung CO; Kim KM; Park CK; Choi MG; Sohn TS; Bae JM; Kim S
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S477-84. PubMed ID: 23274580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 amplification in gastric cancer is a rare event restricted to the intestinal phenotype.
    Cruz-Reyes C; Gamboa-Dominguez A
    Int J Surg Pathol; 2013 Jun; 21(3):240-6. PubMed ID: 23564704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
    Fassan M; Mastracci L; Grillo F; Zagonel V; Bruno S; Battaglia G; Pitto F; Nitti D; Celiento T; Zaninotto G; Fiocca R; Rugge M
    Histopathology; 2012 Nov; 61(5):769-76. PubMed ID: 22882541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays.
    Kim KC; Koh YW; Chang HM; Kim TH; Yook JH; Kim BS; Jang SJ; Park YS
    Ann Surg Oncol; 2011 Oct; 18(10):2833-40. PubMed ID: 21468783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization.
    Im SA; Kim JW; Kim JS; Kim MA; Jordan B; Pickl M; Han SW; Oh DY; Lee HJ; Kim TY; Kim WH; Yang HK; Bang YJ
    Diagn Mol Pathol; 2011 Jun; 20(2):94-100. PubMed ID: 21532492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
    He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
    World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis.
    Fassan M; Pizzi M; Realdon S; Balistreri M; Guzzardo V; Zagonel V; Castoro C; Mastracci L; Farinati F; Nitti D; Zaninotto G; Rugge M
    Hum Pathol; 2013 Sep; 44(9):1804-10. PubMed ID: 23618359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.
    Thompson SK; Sullivan TR; Davies R; Ruszkiewicz AR
    Ann Surg Oncol; 2011 Jul; 18(7):2010-7. PubMed ID: 21267790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma.
    Yoshida H; Yamamoto N; Taniguchi H; Oda I; Katai H; Kushima R; Tsuda H
    Virchows Arch; 2014 Aug; 465(2):145-54. PubMed ID: 24889042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.
    König AM; Reeh M; Dancau AM; Rathjens M; Gros S; Uzunoglu FG; Bockhorn M; Simon R; Sauter G; Marx A; Izbicki JR
    Anticancer Res; 2013 Nov; 33(11):4975-82. PubMed ID: 24222138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio?
    Kumarasinghe MP; de Boer WB; Khor TS; Ooi EM; Jene N; Jayasinghe S; Fox SB
    Pathology; 2014 Apr; 46(3):184-7. PubMed ID: 24614718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
    Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
    J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections.
    Lee S; de Boer WB; Fermoyle S; Platten M; Kumarasinghe MP
    Histopathology; 2011 Nov; 59(5):832-40. PubMed ID: 22092394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan.
    Li JW; Chuang TC; Yang AH; Hsu CK; Kao MC
    Int J Oncol; 2005 Apr; 26(4):933-43. PubMed ID: 15753987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is her-2 status in the primary tumor correlated with matched lymph node metastases in patients with gastric cancer undergoing curative gastrectomy?
    Selcukbiricik F; Erdamar S; Buyukunal E; Serrdengecti S; Demirelli F
    Asian Pac J Cancer Prev; 2014; 15(24):10607-11. PubMed ID: 25605147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.
    Liu W; Zhong S; Chen J; Yu Y
    J Clin Gastroenterol; 2012 Apr; 46(4):e31-7. PubMed ID: 22064554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101).
    Matsusaka S; Nashimoto A; Nishikawa K; Miki A; Miwa H; Yamaguchi K; Yoshikawa T; Ochiai A; Morita S; Sano T; Kodera Y; Kakeji Y; Sakamoto J; Saji S; Yoshida K
    Gastric Cancer; 2016 Jul; 19(3):839-51. PubMed ID: 26265390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ analysis of HER2 mRNA in gastric carcinoma: comparison with fluorescence in situ hybridization, dual-color silver in situ hybridization, and immunohistochemistry.
    Kim MA; Jung JE; Lee HE; Yang HK; Kim WH
    Hum Pathol; 2013 Apr; 44(4):487-94. PubMed ID: 23084583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.